

**Objective**

Xantos Labs seeks long-term capital appreciation primarily by investing in companies which offer strong earnings growth as well as targeted exposures to segments of the economy that provide a natural macro hedge.

**Sector Exposure**

Cash	<3%
Healthcare	33%
Financials	27%
Information Technology	31%
Consumer Discretionary	7%

**Top 5 Holdings**

Medpace Holdings
Progressive Corp
Eli Lilly
NVIDIA
Camtek Ltd

**Operations**

Strategy	Concentrated Long-Only
Advisory Fee	Greater of 2% AUM or \$5/month
Capitalization	All Cap
Performance Fee	None
Lock up	None
Number of Holdings	20

**Note:** Sector Classifications are based on GICS ®. Totals may not equal 100 due to rounding.

**Country Exposure**

United States <sup>a</sup>	84%
International	16%

<sup>a</sup> Includes cash exposure.

**Investment Process**

Simply put, investment outcomes depend on two things: knowing what to invest in and how much to invest. To identify high conviction picks for our investable universe, we conduct a thorough fundamental analysis. We do not use traditional stock screeners or care for them. Rather, we focus on businesses with solid fundamentals and an incredible long-term growth runway that is bolstered by strong macro tailwinds. Secondly, we employ a systematic process to select how much to put into each stock in the portfolio. Overlaying a quantitative/systematic approach helps us ensure a repeatable process. In doing this, we ignore the upside potential of any company but rather focus on minimizing risk of permanent loss of capital – i.e., downside risk – for the entire portfolio. We backtest everything that we do through various market cycles. To reduce risk exposure during downturns, we employ features such as business cycle prediction that quantify the likelihood of a downturn in real-time, helping us strike a balance between aggressiveness and defensiveness in the portfolios. The result is a concentrated long-only portfolio that is tailored to each client's risk tolerance and actively managed to limit downside risk over market cycles.

**Performance (Net of fees)**

	Cumulative Risk Stats			Annualized Total Return			
	Std Dev	Beta	Sharpe Ratio	1 Yr	3 Yr	5 Yr	Since Inception
Xantos Labs (Net)	21.4%	0.8	0.6	29.7%	4.1%	11.3%	13.3%
S&P 500 Index	15.9%	1.0	0.8	29.9%	11.5%	15.1%	14.2%

**Calendar Year Performance**

	Q1-2024	2023	2022	2021	2020	2019	2018	2017	2016
Xantos Labs (Net)	19.5%	15.1%	-34.4%	17.3%	56.2%	17.7%	24.1%	24.4%	-6.9%
S&P 500 Index	10.6%	26.3%	-18.1%	28.7 %	18.4%	31.5%	-4.4%	21.8%	12.0%

Since Inception from 1/1/2016 through 03/31/2024

All performance results are net of fees, dividends/reinvestments, and other adjustments. Investment outcomes based on actual account(s) from the timeframe noted above and for "Aggressive" investment style; clients with "Moderate" or "Conservative" investment styles would have experienced lower returns. The performance results for calendar years 2016 through 2018, exclude those of any of the firm's clients and none of the firm's clients experienced this performance during those periods. In full disclosure of the effects of material market and economic conditions on returns, S&P 500 Index returns are included. Risk Free Rate based on 3-month U.S. Treasury. Past performance does not guarantee future results. Investing carries substantial risk including loss of principal.

## IMPORTANT DISCLOSURES

Xantos Labs, LLC ("Xantos") is an SEC-registered Investment Advisor. Brokerage services are primarily provided to Xantos clients by Alpaca Securities LLC, an SEC-registered broker-dealer, and FINRA/SIPC member.

Nothing in this communication should be construed as tax advice, a solicitation or offer, or recommendation, to buy or sell any security in any jurisdiction where such an offer, solicitation or recommendation would be unlawful or unauthorized. Statements made herein may be outdated and subsequent events may have occurred, information may have changed, that could make any statement in these materials inaccurate or incomplete. The materials presented may contain certain forward looking or promissory language regarding the performance of Xantos or a company; these statements should not be relied upon to make an investment decision. Before investing, consider your investment objectives as certain investments are not suitable for all investors. Please consult with an independent financial advisor before making any investment decisions. The graphs, charts and other visual aids are provided for informational purposes only, not to be used to make investment decisions. Prospective clients must refer to our website, and in particular, our Form ADV for a description of our investment process.

All investing involves risk, including possible loss of principal. Past performance does not guarantee of future results. Performance can vary widely over time, especially for long term investments. There can be no assurance that Xantos' objectives will be achieved or that an investor will receive any desired return on their investment.

The data in this material is based on aggregate of accounts (the "Composite"). The Composite includes all fully discretionary accounts under management and for "Aggressive" investment style; including accounts no longer managed by Xantos and are presented in US Dollars. Accounts with "Moderate" or "Conservative" investment styles would have experienced lower returns. The inception date for the Composite is 01/01/2016. Results are based on Time Weighted Return which was compounded on a daily basis since inception date. Performance results were prepared by Xantos, and have not been compiled, reviewed, or audited by an independent accountant. Performance estimates are subject to future adjustment and revision.

The primary benchmark for the Composite is the S&P 500 Index. In full disclosure of effects of material market and economic conditions on returns, S&P 500 Index returns are included. The S&P 500 Index is a market-value weighted index representing the performance of 500 widely held publicly traded large-capitalization stocks. These indices are used for comparison purposes and are not meant to be indicative of a portfolio's performance, asset composition, or volatility. The performance of the Composite may differ markedly from that of compared indices due to varying degrees of diversification and/or other facts. Return calculations for the Composite are provided in-house. Return calculations for all indices are provided by FactSet, Bloomberg and/or S&P Global. A full schedule of fees for the Firm is available upon request. The collection of fees has a compounding effect on the total rate of return net of investment management fees. All performance results are net of fees, dividends/reinvestments, and other adjustments.

Characteristics calculations use holdings at market close on the stated date, including cash & cash equivalents. Standard deviation is a measure of volatility showing the average deviations of a return series from its mean. Risk-Adjusted Return (Sharpe Ratio), Beta, Standard Deviation and return calculations for the Composite and indices based on Xantos' internal calculation. The Sharpe Ratio is a calculation of a product's risk-adjusted performance over time. The Sharpe Ratio is calculated by taking a product's annualized excess return over a risk-free rate (Xantos uses the 3-Month Treasury Bill as the risk-free rate) and dividing by its annualized standard deviation calculated using daily returns. The Beta is a measure of volatility in comparison to the index as a whole. A Beta of 1.00 indicates same volatility as the index.

Certain information contained herein constitutes "forward-looking statements", which can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target" or "believe" (or the negatives thereof) or other variations there on or comparable terminology. Due to various risks and uncertainties, actual events or results or actual performance may differ materially from those reflected or contemplated in such forward-looking statements. As a result, investors should not rely on such forward-looking statements in making investment decisions. No representation or warranty is made as to future performance or such forward-looking statements.

The data in this material is based on current public information that Xantos considers reliable, but Xantos does not represent that the research or the report is accurate or complete, and it should not be relied on as such. The views and opinions expressed in this are current as of the date of this communication and are subject to change. Financial metrics are subject to future adjustment and revision. Any forecasted metrics may not reflect actual future results. Any securities identified do not represent all of the securities purchased, sold, or recommended for Xantos' clients. Any securities identified do not represent all of the securities purchased, sold, or recommended for clients. It should not be assumed that investments made in the future will be profitable or will equal the performance of any securities referenced.

Please see our full disclosures at [www.xantoslabs.com/legal](http://www.xantoslabs.com/legal)